Shares of Amarin Corp Ads (NASDAQ:AMRN) climbed 2.63% in the past week and soared 29.13% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 7.5% while its year to date performance is at 7.23%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Amarin will report full-year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.22) to ($0.20). The company's revenue was up 45.4% on a year-over-year basis.
A number of other research firms also recently issued reports on AMRN.
Investors and Traders continue to monitor technical levels of shares of Amarin Corporation plc (AMRN). The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. The business's revenue for the quarter was up 45.4% compared to the same quarter a year ago. During the same period in the previous year, the company posted ($0.08) EPS.
A number of brokerages have commented on AMRN. H.C. Wainwright maintained Amarin Corporation plc (NASDAQ:AMRN) rating on Thursday, August 3. ValuEngine upgraded Amarin from a sell rating to a hold rating in a report on Wednesday, December 20th.
Chief Scientific Officer at Amarin Corporation plc, Ketchum Steven B on 2018-01-05 Sell 64683 shares of the company at a price of $4.4. Cantor Fitzgerald maintained it with "Buy" rating and $1000 target in Monday, June 26 report. H.C. Wainwright maintained the shares of AMRN in report on Thursday, June 1 with "Buy" rating.
Among 24 analysts covering RPC (NYSE:RES), 7 have Buy rating, 1 Sell and 16 Hold.
WARNING: "Cantor Fitzgerald Analysts Give Amarin (NASDAQ:AMRN) a $10.00 Price Target" was published by Week Herald and is the sole property of of Week Herald. Amarin Corporation plc's average EBITDA per Share Growth Rate was 0 percent during the past 12 months. The company had a trading volume of 2,571,143 shares, compared to its average volume of 1,743,514.
Amarin Corp Ads (NASDAQ:AMRN)'s 52-week price fluctuated within the range of $4.47 - $2.81.
The company's Average Earnings Estimate for the Current Fiscal quarter is $-0.06, according to consensus of 2 analysts. The stock was sold at an average price of $4.25, for a total value of $545,092.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Since October 5, 2017, it had 0 insider buys, and 3 selling transactions for $1.05 million activity. The disclosure for this purchase can be found here. It is positive, as 10 investors sold Amarin Corporation plc shares while 21 reduced holdings. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company's stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Stevens Capital Management LP acquired a new position in Amarin during the third quarter worth $229,000. Finally, TD Asset Management Inc. purchased a new position in shares of Amarin during the third quarter valued at about $285,000. Wells Fargo And Mn reported 43,435 shares. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company's stock valued at $152,000 after acquiring an additional 5,000 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its position in shares of Amarin by 94.2% in the second quarter. The stock now has Monthly Volatility of 4.29% and Weekly Volatility of 3.15%. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Amarin in the third quarter valued at approximately $226,000. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & global copyright & trademark law.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.